Is Anthropic’s IPO a bad bet, both for investors and society?
What the bull case leaves out

TL;DR
- Author has doubts about Anthropic's IPO valuation, referencing a past accurate prediction about Oracle.
- The bull case for Anthropic assumes continued exponential revenue growth, which the author believes is unlikely.
- Anthropic's revenue growth has already shown signs of slowing down.
- Ambitious promises by Anthropic, especially in medicine, are considered unrealistic.
- The author advises against buying Anthropic stock for the sake of humanity.
From the person who told you that Oracle was at “peak bubble” when it was trading at over $300 (today’s price is around $115), here’s why I (not a professional investor so just giving my own reasoning!) have my doubts about the high valuation for the upcoming Anthropic IPO.
Either way, as a person who has been warning about risks of AI night and day for the last several years, I would like you to consider not buying Anthropic stock for the sake of humanity.
I will get to the moral side of the argument at the end.
But first, the bull case, as I understand it, and then what I think it gets wrong and leaves out.
Part I: The bull case
Anthropic makes strong AI models, and arguably, by a small margin, the best.
Back in October Brad Gerstner made the bull case with this chart:

And there is also this y-axis monstrosity

Both assumed revenue would go up and up.
That brings me to Part II.
Part II: Misconceptions
The first misconception was that revenue would continue to grow exponentially. I have often called that the trillion-pound baby fallacy, after this memorable tweet.

The point was that few exponentials last forever. And, sure enough, Anthropic has already fallen off Q2’s revenue rocket:

The most recent data I have seen shows that the revenue rocket is no longer accelerating as fast as before:

The green line represents the widespread fantasy, and roughly the rocket that Anthropic would have needed to make it as a gargantuan sustainable business. The darker bars on the right show that it has already fallen off the pace—which is why Anthropic probably won’t make it. Q2 was special, at the height of tokenmaxxing and before Chinese models (perhaps thanks to the largesse of Jensen Huang) caught up. Now people have options, and they watch their token spend more carefully, which means revenue has leveled out.
Another misconception is to believe that Dario can deliver on his wilder promises, especially around medicine. As I noted in a recent article, those promises are absolutely absurd. We are more likely to get hit by a meteor.
But what really matters the most is what’s beenleft outof the bull case.